Meeting NewsVideo

IL-15 inhibitor among key celiac research at DDW 2018

WASHINGTON — In this exclusive video, Joseph Murray, MD, of the Mayo Clinic in Rochester, Minn., shares an overview of key research and discussions in celiac disease being shared at Digestive Disease Week.

“Of particular interest are two trials that are being reported using a novel agent that blocks interleukin 15,” he said. “It’s been known now for a few years that interleukin 15 is crucial to the damage that occurs in celiac disease, especially in refractory celiac disease, and we’re going to hear the exciting results of really the largest study ever conducted on refractory celiac disease, and that’s with this new agent AMG-714. We’re excited to hear about the potential benefits that this treatment has for the sickest ... patients with celiac disease. We’re also going to hear about that same agent being used for patients with celiac disease who are continuing to have symptoms and are being challenged with gluten to see if it might be helpful in a more general context.”

Other important celiac highlights include a session on “breaching tolerance” focused on immune response to gluten and other compounds in wheat, and oral presentations on new in vivo models of celiac disease “that could be very helpful for further drug development,” he added.

Disclosures: Murray reports financial relationships with Intrexon, GlaxoSmithKline, Takeda, Celimmune, Innovate, Inova, Torax, Allakos and UCB.

WASHINGTON — In this exclusive video, Joseph Murray, MD, of the Mayo Clinic in Rochester, Minn., shares an overview of key research and discussions in celiac disease being shared at Digestive Disease Week.

“Of particular interest are two trials that are being reported using a novel agent that blocks interleukin 15,” he said. “It’s been known now for a few years that interleukin 15 is crucial to the damage that occurs in celiac disease, especially in refractory celiac disease, and we’re going to hear the exciting results of really the largest study ever conducted on refractory celiac disease, and that’s with this new agent AMG-714. We’re excited to hear about the potential benefits that this treatment has for the sickest ... patients with celiac disease. We’re also going to hear about that same agent being used for patients with celiac disease who are continuing to have symptoms and are being challenged with gluten to see if it might be helpful in a more general context.”

Other important celiac highlights include a session on “breaching tolerance” focused on immune response to gluten and other compounds in wheat, and oral presentations on new in vivo models of celiac disease “that could be very helpful for further drug development,” he added.

Disclosures: Murray reports financial relationships with Intrexon, GlaxoSmithKline, Takeda, Celimmune, Innovate, Inova, Torax, Allakos and UCB.

    See more from Digestive Disease Week